SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

2/14/23 12:38:05 PM ET

Medical/Dental Instruments

Health Care

Get the next $SWAV alert in real time by email

SC 13G/A 1 swav13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) SHOCKWAVE MEDICAL INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 82489T104 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 203,758 6. Shared Voting Power* 0 7. Sole Dispositive Power* 1,012,393 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,012,393 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 2.8% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: SHOCKWAVE MEDICAL INC Item 1(b) Address of Issuer's Principal Executive Offices: 5403 BETSY ROSS DRIVE, SANTA CLARA, CALIFORNIA 95054 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 82489T104 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 14, 2023 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2022

Get the next $SWAV alert in real time by email

Recent Analyst Ratings for

$SWAV

Date	Price Target	Rating	Analyst
4/5/2024		Outperform → Peer Perform	Wolfe Research
3/27/2024	$368.00	Buy	CL King
9/29/2023	$218.00	Neutral	UBS
7/10/2023	$291.00 → $335.00	Equal-Weight → Overweight	Morgan Stanley
5/30/2023	$291.00	Equal-Weight	Morgan Stanley
3/15/2023	$240.00	Buy	Needham
12/16/2022	$285.00	Buy	Deutsche Bank
12/12/2022	$300.00 → $235.00	Overweight → Equal Weight	Wells Fargo

More analyst ratings

SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $SWAV

$SWAV Press Releases

Fastest customizable press release news feed in the world

Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

Sarepta Therapeutics Set to Join S&P MidCap 400

Shockwave Medical Reports First Quarter 2024 Financial Results

$SWAV Market Insights

Live Market Insights

Why Sarepta Therapeutics Stock Is Rising Today

Sarepta Therapeutics To Join S&P Midcap 400, Effective June 3

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M

$SWAV Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ShockWave Medical downgraded by Wolfe Research

CL King initiated coverage on ShockWave Medical with a new price target

UBS initiated coverage on ShockWave Medical with a new price target

$SWAV Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$SWAV Large Ownership Changes

This live feed shows all institutional transactions in real time.

Francis Laura returned 4,784 shares to the company, closing all direct ownership in the company (SEC Form 4)

Moll Frederic H returned 287,521 shares to the company, closing all direct ownership in the company (SEC Form 4)

Papiernik Antoine returned 34,913 shares to the company, closing all direct ownership in the company (SEC Form 4)